ResearchIn-Press PreviewPulmonology
Open Access | 10.1172/jci.insight.160688
1Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
Find articles by
Penke, L.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
Find articles by
Speth, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
Find articles by
Huang, S.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
Find articles by Fortier, S. in: JCI | PubMed | Google Scholar
1Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
Find articles by Baas, J. in: JCI | PubMed | Google Scholar
1Department of Internal Medicine, University of Michigan, Ann Arbor, United States of America
Find articles by
Peters-Golden, M.
in:
JCI
|
PubMed
|
Google Scholar
|
Published July 19, 2022 - More info
There is a paucity of information about potential molecular brakes on the activation of fibroblasts that drive tissue fibrosis. The transcription factor Kruppel-like factor 4 (KLF4) is best known as a determinant of cell stemness and a tumor suppressor. We found that its expression was diminished in fibroblasts from fibrotic lung. Gain- and loss-of-function studies showed that KLF4 inhibits fibroblast proliferation, collagen synthesis, and differentiation to myofibroblasts, while restoring their sensitivity to apoptosis. Conditional deletion of KLF4 from fibroblasts potentiated the peak degree of pulmonary fibrosis and abrogated the subsequent spontaneous resolution that follows in a model of transient fibrosis. A small molecule inducer of KLF4 was able to restore its expression in fibrotic fibroblasts and elicit resolution in an experimental model characterized by more clinically relevant persistent pulmonary fibrosis. These data identify KLF4 as a pivotal brake on fibroblast activation whose induction represents a new therapeutic approach in fibrosis of the lung, and perhaps other organs.